Related Experiment Video
Updated: May 10, 2026
13:28
Methodology for Sputum Induction and Laboratory Processing
Published on: December 17, 2017
Differences in plasma and sputum biomarkers between COPD and COPD-asthma overlap
Hiroshi Iwamoto1, Jing Gao, Jukka Koskela
1Pulmonary Division, University of Helsinki and Helsinki University Central Hospital, Helsinki.
The European Respiratory Journal
|June 25, 2013
Summary
Biomarkers like neutrophil gelatinase-associated lipocalin (NGAL) in sputum may help distinguish chronic obstructive pulmonary disease (COPD)-asthma overlap from COPD alone. This finding aids in understanding airway inflammation in complex respiratory conditions.
Area of Science:
- Pulmonology
- Biomarker Discovery
- Respiratory Medicine
Background:
- Chronic obstructive pulmonary disease (COPD)-asthma overlap pathophysiology is poorly understood.
- No prior studies have investigated plasma or sputum biomarkers in overlap patients.
- Understanding differences between overlap, COPD, and asthma is crucial for diagnosis and treatment.
Purpose of the Study:
- To investigate four potential COPD biomarkers: surfactant protein A (SP-A), soluble receptor for advanced glycation end-products (sRAGE), myeloperoxidase (MPO), and neutrophil gelatinase-associated lipocalin (NGAL).
- To clarify similarities and differences in biomarker profiles between COPD-asthma overlap, COPD, and asthma patients.
Main Methods:
- Enzyme immunoassay/ELISA was used to measure plasma SP-A and sRAGE, and induced sputum MPO and NGAL.
- 134 subjects were analyzed: nonsmokers, smokers, asthma, COPD, and COPD-asthma overlap patients.
- Comparative analysis was performed between the different patient groups.
Main Results:
- COPD-asthma overlap patients showed significantly elevated sputum MPO and plasma SP-A compared to asthma patients.
- Plasma sRAGE levels were reduced in COPD-asthma overlap patients compared to asthma patients.
- Sputum NGAL was significantly elevated in COPD-asthma overlap compared to COPD, differentiating the two groups.
Conclusions:
- Increased sputum NGAL may characterize COPD-asthma overlap, indicating enhanced neutrophilic airway inflammation or epithelial injury.
- Biomarker profiles differ significantly between COPD-asthma overlap, COPD, and asthma.
- NGAL shows potential as a diagnostic biomarker for differentiating COPD-asthma overlap from COPD.
Related Concept Videos
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:19Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations
Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet cell...
01:24Chronic Obstructive Pulmonary Disease
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
01:13Asthma III: Clinical Manifestations
Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...